Methylenedioxynitazene

Methylenedioxynitazene
Identifiers
	IUPAC name 2-(2-((1,3-benzodioxol-5-yl)methyl)-5-nitro-1H-benzo[d]imidazol-1-yl)-N,N-diethylethan-1-amine;
Chemical and physical data
Formula	C21H24N4O4
Molar mass	396.447 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCn4c(Cc2ccc1OCOc1c2)nc3cc([N+]([O-])=O)ccc34;
	InChI InChI=InChI=1S/C21H24N4O4/c1-3-23(4-2)9-10-24-18-7-6-16(25(26)27)13-17(18)22-21(24)12-15-5-8-19-20(11-15)29-14-28-19/h5-8,11,13H,3-4,9-10,12,14H2,1-2H3; Key:RRRJUZFZCVIDSM-UHFFFAOYSA-N;

Methylenedioxynitazene (3',4'-Methylenedioxynitazene) is a benzimidazole derivative which has been sold as a designer drug over the internet and presumably has opioid effects. It is an analogue of etonitazene where the benzyl ring is substituted with a 3,4-methylenedioxy ring system rather than an ethoxy group. It was first reported in the UK in early 2024.^[1]

References[edit]

^ "Fourth addendum to ACMD report on the use and harms of 2-benzyl benzimidazole ('nitazene') and piperidine benzimidazolone ('brorphine-like') opioids" (PDF). Advisory Council on the Misuse of Drugs. 5 April 2024.

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

[1] "Fourth addendum to ACMD report on the use and harms of 2-benzyl benzimidazole ('nitazene') and piperidine benzimidazolone ('brorphine-like') opioids" (PDF). Advisory Council on the Misuse of Drugs. 5 April 2024.

[1]

See also[edit]

References[edit]